Bausch + Lomb Future Growth
Future criteria checks 3/6
Bausch + Lomb is forecast to grow earnings and revenue by 65.7% and 6.2% per annum respectively. EPS is expected to grow by 66.1% per annum. Return on equity is forecast to be 5.4% in 3 years.
Key information
65.7%
Earnings growth rate
66.1%
EPS growth rate
| Medical Equipment earnings growth | 17.0% |
| Revenue growth rate | 6.2% |
| Future return on equity | 5.4% |
| Analyst coverage | Good |
| Last updated | 24 May 2024 |
Recent future growth updates
Recent updates
Bausch + Lomb's Bet-The-Farm Xiidra Acquisition Is Looking Questionable, But Miebo Could Make The Stock A Winner
May 24Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 32% Below Their Intrinsic Value Estimate
Apr 30
Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?
Mar 25Many Still Looking Away From Bausch + Lomb Corporation (NYSE:BLCO)
Feb 19Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound
Jan 31Bausch + Lomb Corporation's (NYSE:BLCO) Intrinsic Value Is Potentially 34% Above Its Share Price
Jan 14Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)
Nov 08Why Investors Shouldn't Be Surprised By Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S
Nov 03An Intrinsic Calculation For Bausch + Lomb Corporation (NYSE:BLCO) Suggests It's 46% Undervalued
Aug 15Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease
Aug 09These Return Metrics Don't Make Bausch + Lomb (NYSE:BLCO) Look Too Strong
May 09Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 24% Below Their Intrinsic Value Estimate
Mar 28Bausch + Lomb Non-GAAP EPS of $0.23 beats by $0.01, revenue of $996M beats by $32.08M
Feb 22Bausch + Lomb's photodynamic laser gets FDA approval for use with Visudyne
Feb 01Bausch + Lomb: Still A Favorable Risk-To-Reward Prospect
Jan 24Bausch + Lomb acquires AcuFocus for cataract lens
Jan 17Bausch + Lomb says Joseph Papa to serve as CEO until at least March next year
Dec 22Bausch + Lomb stock rises on FDA nod for contact lens rehydrating drops
Dec 13Bausch + Lomb: A Solid Play In Challenging Economic Times
Nov 09Bausch + Lomb reports Q3 mixed earnings; narrows FY22 guidance range
Nov 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5,199 | 129 | 776 | 691 | 8 |
| 12/31/2025 | 4,944 | -62 | 512 | 576 | 12 |
| 12/31/2024 | 4,658 | -236 | 310 | 313 | 13 |
| 3/31/2024 | 4,314 | -337 | -131 | 80 | N/A |
| 12/31/2023 | 4,146 | -260 | -198 | -17 | N/A |
| 9/30/2023 | 3,969 | -207 | -20 | 127 | N/A |
| 6/30/2023 | 3,904 | -141 | -60 | 106 | N/A |
| 3/31/2023 | 3,810 | -104 | 116 | 286 | N/A |
| 12/31/2022 | 3,768 | 6 | 170 | 345 | N/A |
| 9/30/2022 | 3,773 | 58 | 144 | 348 | N/A |
| 6/30/2022 | 3,780 | 136 | 398 | 594 | N/A |
| 3/31/2022 | 3,773 | 175 | 482 | 688 | N/A |
| 12/31/2021 | 3,765 | 182 | 680 | 873 | N/A |
| 9/30/2021 | 3,708 | -78 | 636 | 845 | N/A |
| 6/30/2021 | 3,675 | -53 | 539 | 776 | N/A |
| 3/31/2021 | 3,517 | -44 | 370 | 618 | N/A |
| 12/31/2020 | 3,412 | -18 | 263 | 522 | N/A |
| 12/31/2019 | 3,778 | 298 | 619 | 799 | N/A |
| 12/31/2018 | 3,665 | 710 | 662 | 763 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLCO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: BLCO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BLCO is expected to become profitable in the next 3 years.
Revenue vs Market: BLCO's revenue (6.2% per year) is forecast to grow slower than the US market (8.4% per year).
High Growth Revenue: BLCO's revenue (6.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BLCO's Return on Equity is forecast to be low in 3 years time (5.4%).